- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Frank Porreca: How Advancements in CGRP Inhibitors Paved the Way for Migraine Prevention Therapies
The CGRP story is really based on reverse translation and other observations in humans will be pursued along that same model, said Frank Porreca, PhD, professor of pharmacology and anesthesiology at the University of Arizona and a member of the Department of Collaborative Research at Mayo Clinic in Arizona.
The CGRP story is really based on reverse translation and other observations in humans will be pursued along that same model, said Frank Porreca, PhD, professor of pharmacology and anesthesiology at the University of Arizona and a member of the Department of Collaborative Research at Mayo Clinic in Arizona.
Transcript:
The American Journal of Managed Care® (AJMC®): How have advancements in CGRP inhibitors paved the way for future research into migraine prevention therapies?
Dr. Porreca: The CGRP story is really again, based on this idea of reverse translation. Astute clinical observation that CGRP levels were increased during a migraine attack in humans led to investigation of CGRP mechanisms at preclinical levels and then development of therapeutics. The actual development of therapeutics had the characteristics, not only of being tool compounds that were interesting in the laboratory, but that could actually be used in humans as therapies. I think that there are other observations in humans that will be pursued along that same model. So exactly what's happening in humans evaluated mechanistically and then try to advance that therapy. Obviously, therapies that can be more broadly effective, possibly than anti-CGRP therapies, or can be used in conjunction with CGRP therapies will be hugely important.
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More
